Pnd111 - Eliciting Preferences in Relapsing-Remitting Multiple Sclerosis – A Brazilian Study Using a Multicriteria Decision Analysis (Mcda) Approach

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2077
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cognitive Impairments in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

Multiple Sclerosis
Neurology
2008English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Multiple Sclerosis International
Neurology
2015English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Stressful Events Increase Exacerbations in Relapsing-Remitting Multiple Sclerosis

BMJ
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy